Matches in DBpedia 2015-10 for { ?s ?p "ALKS-5461 is a combination drug formulation of buprenorphine and samidorphan which is under development by Alkermes as an adjunct to antidepressant therapy in treatment-resistant depression (TRD). It is also under development by Alkermes as a treatment for cocaine dependence, which is being funded by a grant from the National Institute on Drug Abuse (NIDA)."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- ALKS-5461 abstract "ALKS-5461 is a combination drug formulation of buprenorphine and samidorphan which is under development by Alkermes as an adjunct to antidepressant therapy in treatment-resistant depression (TRD). It is also under development by Alkermes as a treatment for cocaine dependence, which is being funded by a grant from the National Institute on Drug Abuse (NIDA).".
- ALKS-5461 comment "ALKS-5461 is a combination drug formulation of buprenorphine and samidorphan which is under development by Alkermes as an adjunct to antidepressant therapy in treatment-resistant depression (TRD). It is also under development by Alkermes as a treatment for cocaine dependence, which is being funded by a grant from the National Institute on Drug Abuse (NIDA).".